HLA-A and acute myeloid leukemia: It was studied in a phase II study, in which 22 patients with AML (of whom nine patients had HLA-A*02:01) in CR1 were treated with GPS, administered together with G-CSF at least for six vaccinations, with the possibility of six additional monthly doses in patients remaining in CR1.